BioWorld

Nov. 22, 2002

Lundbeck Acquiring Synaptic, CNS Pipeline For $121M In Cash

Synaptic Pharmaceutical Corp. signed a definitive merger agreement with like-minded central nervous system-focused H. Lundbeck A/S in a deal worth about $121 million. (BioWorld Today) Read More

Jun Gene Encodes Enzyme That Links Obesity, Diabetes In Tissue Inflammation With Drug Designs

Inspire Starts Phase III Trial Of Drug For Allergic Rhinitis

Other News To Note

Inflazyme In Line For Up To $90M After Expanding Deal With Aventis

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...